Fusion Antibodies sees annual revenues rise almost 80%
Clarendon portfolio company Fusion Antibodies the pharmaceutical contract research company have said full-year revenues rose almost 80 per cent in the year to the end of March. The company said revenues rose to £3.9 million (€4.3 million), up from £2.2 million in the same period a year earlier. The increase has been well flagged by […]
Fusion Antibodies sees annual revenues rise almost 80% Read More »